Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 220Rectal Neoplasms 137Stomach Neoplasms 95Colonic Neoplasms 87Pancreatic Neoplasms 82Esophageal Neoplasms 71Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 43Head and Neck Neoplasms 42Adenocarcinoma Of Esophagus 37Neoplasms 36Breast Neoplasms 35Esophageal Squamous Cell Carcinoma 27Carcinoma, Hepatocellular 22Cholangiocarcinoma 21Adenocarcinoma 17Nasopharyngeal Carcinoma 16Bile Duct Neoplasms 14Gallbladder Neoplasms 13Carcinoma, Squamous Cell 13Biliary Tract Neoplasms 13Anus Neoplasms 13Urinary Bladder Neoplasms 11Liver Neoplasms 10Carcinoma 9Nasopharyngeal Neoplasms 8Colorectal Cancer Metastatic 8Peritoneal Neoplasms 7Recurrence 6Ovarian Neoplasms 6

Interventions

STA 9090 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophagogastric Cancer × Fluorouracil × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡